… Non–small cell lung cancer (NSCLC) with activating mutations in the epidermal growth …
erlotinib. However, secondary somatic EGFR mutations (eg, T790M) confer resistance to erlotinib…

… Importance Erlotinib is a standard first-line therapy for patients with epidermal growth factor
… non–small cell lung cancer (NSCLC). Median progression-free survival (PFS) with erlotinib is …

… tumor growth and progression in many cancers1, 2 and EGFR overexpression occurs in up
to 80% of non-small cell lung cancers (NSCLC).3, 4 Erlotinib … patients with relapsed NSCLC. …

… Erlotinib is a small molecule that inhibits the tyrosine kinase activity of epidermal growth …
in patients with non–small-cell lung cancer, pancreatic cancer, and glioblastoma multiforme. …

… In our study, erlotinib patients were included without knowledge of the EGFR mutation status
in tumour tissue. As erlotinib is now increasingly used in pre-selected patients, the duration …

… Eight percent of elderly erlotinib patients had an objective response, and 70% had a best
response of stable disease compared with 9% and 59% of young patients, but these …

… approval, patients with stage IIIB or IV NSCLC who received erlotinib from 2007 … Cancer
staging edition was used to describe patient stage. Patients who received ≤ 1 week of erlotinib …

… -doublet chemotherapy in patients with advanced non-small-cell lung cancer (NSCLC) is …
TKI) erlotinib is an established option for second-line treatment of patients with advanced …

… ), have been extensively developed in non-small cell lung cancer (NSCLC). Based on the
… , and erlotinib was approved by the FDA in 2004 for the treatment of patients with relapsed …

… In patients who had squamous cell histology, erlotinib resulted in a superior TTP compared
with … arm, whereas the incidence of grade 3 and 4 skin rash was higher in the erlotinib arm. …